RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC

This study examines whether standard RECIST criteria — the method doctors use to measure how well a treatment is working based on tumor size on scans — accurately reflects how well targeted therapies work in people with advanced non-small cell lung cancer (NSCLC) that has a specific driver gene mutation. **You may be eligible if...** - You are 18 or older - You have advanced NSCLC at Stage IIIB or Stage IV - Your tumor has a known driver gene mutation (such as EGFR, ALK, C-MET, ROS1, RET, or HER2) - You are about to start or are on first-line targeted therapy for your cancer - Your overall health is good (ECOG 0–2) - You have measurable tumors on imaging - Your tumor markers are significantly elevated **You may NOT be eligible if...** - Your lung cancer does not have a driver gene mutation - You have already received prior treatment lines - You do not have measurable disease or do not meet blood count/organ function requirements Talk to your doctor to see if this trial is right for you.